Liver News and Research

RSS

Scientists show how sorafenib can be dangerous to the heart

Scientists for the first time have evidence showing how a widely used type of "targeted" cancer drug can be dangerous to the heart.

7 Nov 2012

Excessive turnover of placental cells may trigger unnatural increase in blood pressure

Excessive turnover of cells in the placenta may trigger an unnatural increase in blood pressure that puts mother and baby at risk, researchers say.

7 Nov 2012

Liver transplant waitlist mortality not simply due to lack of donor organs: Study

The majority of patients on the liver transplant waitlist who died received offers of high-quality donated livers that were declined prior to their death, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. Therefore, efforts other than simply increasing the availability of donated livers or the number of offers are needed to substantially reduce the deaths among those waiting for a transplant.

7 Nov 2012

Treatment with AMG 145 reduces LDL cholesterol

Amgen today announced that results from the LAPLACE-TIMI 57 and MENDEL Phase 2 studies evaluating AMG 145 in hypercholesterolemic patients with or without statins, respectively, showed that treatment with AMG 145 resulted in a statistically significant reduction in low-density lipoprotein (LDL) cholesterol.

7 Nov 2012

SCYNEXIS announces results from SCY-635 Phase 2a study on HCV

SCYNEXIS, Inc. today announced that the results of a Phase 2a study of lead candidate SCY-635 for the treatment of the hepatitis C virus (HCV) will be the subject of an oral presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place from November 9-13 in Boston, Massachusetts.

7 Nov 2012

AMG 145 can reduce LDL cholesterol levels by up to 66% after 12 weeks

For many people with high cholesterol, statins serve as the first line of treatment. However, some patients are unable to effectively reduce their low-density lipoprotein cholesterol (LDL cholesterol) or "bad cholesterol" levels with statins, the most commonly used medication to treat high cholesterol, due to their bodies' inability to tolerate or sufficiently respond to the medicine.

7 Nov 2012

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

6 Nov 2012

Selective blocking of HDAC11 inhibitor would act exclusively on tumor cells

Several substances inhibiting so-called HDAC enzymes have been studied in trials searching for new anti-cancer drugs in recent years. "Trials have shown that HDAC inhibitors are very effective in arresting growth of cultured cancer cells. But apart from a very rare type of lymphoma, these drugs unfortunately do not clinically affect malignant tumors," says Prof. Dr. Olaf Witt, who heads a research department at DKFZ and is pediatrician at the Center for Child and Adolescent Medicine of Heidelberg University Hospital.

6 Nov 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.

6 Nov 2012

Intravenous infusion of HDL cholesterol could reduce risk of subsequent heart attack

An intravenous infusion of good cholesterol could reduce the risk of a subsequent heart attack, researchers reported at the American Heart Association's Scientific Sessions 2012.

6 Nov 2012

Inhibition of NOX4 enzyme plays an important role in liver fibrosis

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) have led a study published in PLoS One showing that the inhibition of a family member of NADPH oxidase enzyme, NOX4, plays an important role in liver fibrosis.

5 Nov 2012

Living liver donors have QoL advantage

Living liver donors have a better quality of life than the general population, show the results of a Japanese study.

5 Nov 2012

Study highlights potential treatment that reduces kidney growth

Autosomal-dominant polycystic kidney disease (ADPKD) is one of the most common genetic disorders, affecting one in every 1,000 people and responsible for up to ten percent of patients on dialysis worldwide. The disease is characterized by the development of cysts that lead to progressive kidney failure and necessitate dialysis or a kidney transplant in most patients aged around fifty. Moreover, the persistent cyst growth causes high blood pressure and painful complications.

5 Nov 2012

Bristol-Myers Squibb welcomes decision by NICE to recommend Yervoy for advanced melanoma

Today, Bristol-Myers Squibb is pleased to welcome the decision by The National Institute for Health and Clinical Excellence (NICE) to recommend Yervoy (ipilimumab) for the treatment of previously-treated advanced (unresectable or metastatic) melanoma within the Final Appraisal Determination (FAD).

3 Nov 2012

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Amgen will present data from four Phase 2 trials of AMG 145, an investigational fully human monoclonal antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotein cholesterol, or "bad" cholesterol from the blood, at the upcoming American Heart Association Scientific Sessions 2012.

3 Nov 2012

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

An international effort led by researchers at the Perelman School of Medicine at the University of Pennsylvania has resulted in positive phase 3 clinical trial results for a new medicine to treat patients suffering from a rare and deadly cholesterol disorder.

3 Nov 2012

NY-Presbyterian/CUMC wins two Transplant Program Awards from HSS

NewYork-Presbyterian Hospital/Columbia University Medical Center was named a recipient of two Transplant Program Awards from the U.S. Department of Health and Human Services (HSS) for its outstanding performance on liver and lung transplantation.

3 Nov 2012

University of Cambridge forms new spin-out company to supply hIPSC-derived cells

The potential therapeutic applications of stem cells - such as regenerating damaged tissues or organs - have generated a great deal of interest over the past decade. While these types of applications are exciting, it is a long journey from lab to clinic. The most immediate impact of stem cells on human health will most likely come from their use in the development of new drugs.

3 Nov 2012

UC Irvine, Cal State Fullerton partner to help reduce cancer disparities in Orange County

Researchers from UC Irvine's Chao Family Comprehensive Cancer Center and California State University, Fullerton's Health Promotion Research Institute have formed a partnership to help reduce cancer disparities in Orange County.

2 Nov 2012

Developing comorbid conditions post-liver transplant reduces donor quality of life

Researchers in Japan report that health-related quality of life (HRQOL) for donors following living donor liver transplantation (LDLT) was better than the general Japanese population (the norm). This study—one of the largest to date—found that donors who developed two or more medical problems (co-morbidities) after donation had significantly decreased long-term HRQOL.

2 Nov 2012

Liver News and Research

Scientists show how sorafenib can be dangerous to the heart

Excessive turnover of placental cells may trigger unnatural increase in blood pressure

Liver transplant waitlist mortality not simply due to lack of donor organs: Study

Treatment with AMG 145 reduces LDL cholesterol

SCYNEXIS announces results from SCY-635 Phase 2a study on HCV

AMG 145 can reduce LDL cholesterol levels by up to 66% after 12 weeks

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

Selective blocking of HDAC11 inhibitor would act exclusively on tumor cells

Alnylam third quarter 2012 revenues decrease to $16.8 million

Intravenous infusion of HDL cholesterol could reduce risk of subsequent heart attack

Inhibition of NOX4 enzyme plays an important role in liver fibrosis

Living liver donors have QoL advantage

Study highlights potential treatment that reduces kidney growth

Bristol-Myers Squibb welcomes decision by NICE to recommend Yervoy for advanced melanoma

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

NY-Presbyterian/CUMC wins two Transplant Program Awards from HSS

University of Cambridge forms new spin-out company to supply hIPSC-derived cells

UC Irvine, Cal State Fullerton partner to help reduce cancer disparities in Orange County

Developing comorbid conditions post-liver transplant reduces donor quality of life

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News